Eisai reported strong Q3 2024 performance driven by its leading products, particularly LEQEMBI, which saw robust sales growth across key regions. Management expressed confidence in achieving its ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Hyundai Venue SX Opt Turbo Rs. 15.36 Lakh * Hyundai Venue SX DT Diesel Rs. 15.52 Lakh * Hyundai Venue SX Opt Turbo DT Rs. 15.54 Lakh * Hyundai Venue SX Opt Knight Turbo Rs. 15.61 Lakh * Hyundai ...
(RTTNews) - Biogen Inc. (BIIB), a biotechnology company and Eisai Co., Ltd. On Friday provided an update on the regulatory review of lecanemab as a treatment for early Alzheimer's disease or AD in ...
Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...
Tata Consultancy Services (TCS) will open its office in Visakhapatnam within the next three months, IT Minister Nara Lokesh said, adding that the IT major will initially begin operations from a ...
Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what they’ve said is an ongoing … ...
Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab-irmb) has been approved by the US Food and Drug Administration (FDA) for monthly maintenance dosing. The anti-amyloid drug was ...
Credit: Chinnapong/Shutterstock. The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen’s Leqembi (lecanemab-irmb) for maintenance ...
Eisai (TYO: 4523) and Biogen (Nasdaq: BIIB) have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing regimen for Leqembi (lecanemab). Already approved ...
Additionally, a monthly dosing schedule for Leqembi “may be easier for patients and care partners to continue treatment,” potentially helping with the drug’s uptake, according to Eisai’s press ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback